|
Lloyd L. Tran Lloyd L. Tran is a distinguished scientist with over 25 years of experience in drug discovery and business development within the pharmaceutical industry. He currently serves as the Chairman and Chief Executive Officer of Biomed Industries, Inc., headquartered in San Jose, California. (https://www.biomedind.com) Biomed Industries, Inc. operates several subsidiaries, including Biomed Pharmaceutical, Inc., NeuroActiva, Inc., Biomed Green, LLC, MedAware Systems, Inc., and Biomed AI, LLC. Early Career in Drug Discovery Lloyd began his career as a scientist in drug discovery at prominent pharmaceutical companies such as G.D. Searle, Monsanto, and Pfizer. In the early 1990s, Lloyd played an important role in the development of Artemether for malaria treatment in collaboration with the research team of Chinese Academy of Sciences. He coordinated clinical trials for Artemether oral medicine with support from the World Health Organization (WHO) and the Walter Reed Army Institute of Research in Washington, D.C. This effort led to its approval in over 80 countries, including the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) in 2009. Notably, the head of the Chinese research team, Youyou Tu, who discovered qinhaosu (artemisinin), an analogue of Artemether, was awarded the Nobel Prize in Medicine in 2015 for her groundbreaking work on this novel therapy against malaria. The developer of NA-831 for the treatment of Alzheimer's Disease Following the success of Artemether, Lloyd shifted his focus to neurodegenerative diseases after his father began exhibiting symptoms of Alzheimer’s disease (AD). For decades, Alzheimer’s research was dominated by the amyloid hypothesis, which attributes the disease to amyloid beta plaques in the brain. Despite significant investments, drugs targeting this hypothesis—including Aducanumab and Lecanemab—failed to deliver meaningful benefits to patients, leaving Alzheimer’s disease without an effective, disease-modifying treatment. Lloyd pioneered the Neurogenesis Hypothesis, which posits that Alzheimer’s disease impairs the brain’s ability to generate new neurons in the hippocampus, leading to memory loss and cognitive decline. This breakthrough concept led to the development of NA-831, a novel drug designed to promote neurogenesis, restore memory, and improve cognitive function. NA-831 which is based on mechanism of action of neurogenesis, directly related to restoring memory loss and improvement of cognitive improvement. Clinical trials for NA-831 have demonstrated safety and efficacy in patients with mild to moderate Alzheimer’s disease. Biomed Industries plans to advance the drug into Phase 3 clinical trials for both treatment and prevention. THE DEVELOPER OF OTHER NEW DRUGS Under Lloyd’s leadership, Biomed Industries has developed a robust pipeline targeting neurological, metabolic, cardiovascular, and rare diseases. Current programs include: NA-704: for Amyotrophic Lateral Sclerosis (ALS) (Phase 2B) A-831: for Mild and Moderate Alzheimer’s Disease (Phase 2B/3) NA-901: for Major Depressive Disorder (Phase 2B/3) NA-911: for Stroke (Phase 2A) NA-921: for Rett Syndrome and Fragile X (Phase 2B/3) NA-931: for Diabetes Obesity (Phase 2B/3) NA-941: for Metabolic dysfunction-associated steatohepatitis (MASH) For more information, please visit the website of Biomed Industries, Inc.
CONTACT: To contact Lloyd Tran, please complete an online form. Thank you.. -------- © 2024. Lloyd Tran- All Rights Reserved |
|---|
